Friday, 16 October 2026European Markets

PROACTIS SA Stock Went Up By Over 21% In The Last 10 Sessions

Loading stream...

proactis sa, a provider of source-to-pay software solutions and subsidiary of proactis euro hedgeco limited, experienced an amazing 21.95% surge over just 10 sessions - following five consecutive losses over six days; its stock value has rebounded from eur0.08 to eur0.10. as a result, proactis sa contributed positively to cac 40 index, increasing by 0.29% to reach eur7,4977.78 while continuing its three day winning streak.

proactis sa's shift in share performance

proactis sa's shares made a dramatic shift this week, closing at eur0.110 significantly lower than their 52-week high of eur0.15, as part of an effort by software company proactis to control losses.

the company's profitability

the company's trailing twelve-month earnings per share (eps) are currently negative eur0.01, reflecting strains to its profitability. furthermore, its return on equity for that time frame stands at an unimpressive -3.88% which shows their difficulty turning equity investments into profits.

trading scenario

proactis sa's shares are trading above their 50-day moving average of eur0.10 but remain below the 200-day moving average, suggesting mixed market perceptions regarding the stock's potential.

declining quarterly revenue growth

quarterly revenue growth at proactis sa has shrunk 3.6% year-on-year to $14.11 million for the trailing 12 months, prompting traders and investors to proceed with caution when trading its stock. with revenue decreasing year-over-year and earnings per share remaining below zero, traders and investors should exercise extreme care in handling proactis sa stocks.

final thoughts

keep an eye on proactis sa's future corporate actions and market landscape, which both exert great sway over its stock. financial literacy helps individuals make informed decisions to minimize any financial risks. this analysis of proactis sa serves as an ideal baseline for ongoing monitoring.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com